Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys Expanded Access in HBeAg-negative Chronic Hepatitis B
NCT01787279Phase 4Completed
- Sponsor
- Roche
- Start
- Jan 2006
- Primary completion
- May 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB), sponsored by Roche. Primary endpoints: Percentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 72, Percentage of Participants Achieving Normalization of Alanine Aminotransferase at Week 72 and 1 more. Started Jan 2006; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01787279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787279.